hrp0098fc7.6 | GH and IGFs | ESPE2024

Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) over 12 to 24 Months on Treatment

Petriczko Elzbieta , Cassorla Fernando , Investigator Group OraGrowtH210 , Research Team OraGrowtH212 , Bruchey Aleksandra , Smith Christopher , L. Brincks Erik , C. McKew John , O. Thorner Michael , “Duke” Pitukcheewanont Pisit

Background: LUM-201, a potent long-acting oral GH secretagogue (GHS), acts on the GHS Receptor-1a to induce GH secretion. The best candidates for this investigative oral treatment are pre-pubertal children with moderate GHD (standard stimulation testing peak GH between ≥3 <10ng/ml) that respond positively to the LUM-201 Predictive Enrichment Marker (PEM) test (Bright et al JES, 2021). PEM positive responders have basal serum IGF-1 >30ng/ml and a peak ...